The Food and Drug Administration (FDA) has approved Myxredlin (insulin human in 0.9% sodium chloride injection; Baxter), the first ready-to-use insulin for intravenous (IV) infusion for use in acute care settings under medical supervision.
Myxredlin is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The premixed, ready-to-use formulation of Myxredlin uses Baxter’s proprietary Galaxy container technology which allows the product to have a longer shelf life when stored at room temperature.
“When a patient requires intravenous insulin in the hospital, pharmacists have to manually admix insulin for treatment. With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals,” said Robert Felicelli, president, Pharmaceuticals, Baxter.
Myxredlin is a sterile, preservative-free solution supplied as 100 units/100mL of insulin human in 0.9% sodium chloride in a single-dose container with a shelf life of 30 days at room temperature or 24 months if refrigerated in the original container.
Myxredlin is expected to be available before the end of the year.
For more information visit baxter.com.